Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam

56Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: Our objective was to evaluate the influence of cytochrome P450 (CYP) 2C9 polymorphisms on the pharmacokinetics and pharmacodynamics of the nonsteroidal anti-inflammatory drug piroxicam. Methods: Thirty-five healthy subjects with CYP2C9 genotypes *1/*1 (n = 17), *1/*2 (n = 9), and *1/*3 (n = 9) received a single oral dose of piroxicam (20 mg). Blood samples were collected at various time points up to 240 hours for measurements of the concentrations of piroxicam and thromboxane B2 (TXB2). Results: Piroxicam's area under the plasma concentration-time curve from time 0 to infinity and oral clearance corrected for body weight were 154 ± 37 μg · mL-1 · h and 2.0 ± 0.5 mL · h-1 · kg-1, respectively, in CYP2C9*1/*1 individuals, as compared with 256 ± 97 mL · h-1 (P = .002) and 1.3 ± 0.4 mL · h -1 · kg-1 (P = .002), respectively, in CYP2C9*1/*2 individuals and 259 ± 95 mL · h -1 (P = .002) and 1.3 ± 0.4 mL · h-1 · kg-1 (P = .002), respectively, in CYP2C9*1/*3 individuals. There were no significant differences between CYP2C9*1/ *2 and CYP2C9*1/*3 individuals in these pharmacokinetic parameters (P = .95 for area under the plasma concentration-time curve from time 0 to infinity and P = .94 for oral clearance corrected for body weight). The formation of TXB2, reflecting cyclooxygenase type 1 activity, showed significant differences in the area above the effect-time curves (expressed as percent of baseline TXB2 · h) between CYP2C9*1/*1 (10,190 ± 2632) and either CYP2C9*1/*2 (19,255 ± 1,291 [P = .00003]) or CYP2C9*1/*3 (18,241 ± 2397 [P = .00003]). The minimum serum TXB2 concentration, however, did not differ among the different genotypes (P = .32, ANOVA). Conclusion: Piroxicam's oral clearance was impaired and its inhibitory effect on cyclooxygenase 1 activity was increased in CYP2C9*1/*2 or CYP2C9*1/*3 individuals, as compared with CYP2C9*1 homozygous individuals. Copyright © 2005 by the American Society for Clinical Pharmacology and Therapeutics.

Cite

CITATION STYLE

APA

Perini, J. A., Vianna-Jorge, R., Brogliato, A. R., & Suarez-Kurtz, G. (2005). Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clinical Pharmacology and Therapeutics, 78(4), 362–369. https://doi.org/10.1016/j.clpt.2005.06.014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free